



37- 4120 Ridgeway Drive, Mississauga, Ontario L5L 5S9 Canada www.canaquest.com Tel: 416-704-3040, Fax: 416-352-5712

CanaQuest Medical Corp Executive Overview - a life science / pharmaceutical company

September 1st, 2020

CanaQuest Medical Corp is developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, at Western University, London, Ontario Canada. Dr. Laviolette is a scientific veteran with over 14 years of research experience in the field of mental health and cannabinoids and he oversees a dedicated team of 13 scientists.

Dr. Laviolette has made two amazing discoveries:

1) **Mentanine**[®], Omega3 + CBD, non-psychotic formula (Provisional Patent filed) addressing mental health with significantly increased efficacy while reducing dosage, capable of acting on mental health issues inside the Central Nervous System (CNS) by crossing the Blood Brain Barrier (BBB).

2) **Mentabinol**[®], THC + L-Theanine formulation (International Patent filed) as a safer alternative to all other THC products, addressing anxiety, depression, schizophrenia and Post Traumatic Stress Disorder “PTSD”, while protecting all THC users from negative psychiatric side-effects caused by THC.

Based on successful pre-clinical trial results, CanaQuest is planning to complete human trials and seek regulatory approval for **Mentanine**[®]Rx by applying for a Drug Identification Number “DIN number” with the US-based Food and Drug Administration (FDA) and Health Canada. The Company believes the FDA and Health Canada approval process will be significantly reduced because of the quality of the pre-clinical work and the recent regulatory approvals which have been provided for other products containing CBD and THC. Regulatory approvals will give CanaQuest the legal right to sell Rx products as a approved drugs Over The Counter in every pharmacy in the world.

The company is also in discussions with a pharmaceutical company to formalize a collaboration, production, and a distribution agreement. Simultaneously, together with other potential pharma partners, the company is in the process of organizing Human Trials to prove the small dosage efficacy and safety data following randomized double-blind, placebo-controlled trials.

Mentanine[®] (Omega3 compounds + CBD isolate - pharma grade - highly bioavailable formulation) was produced and successfully tested for quality and safety by third party laboratories in the USA and Canada. Results from pre-clinical trials addressing anxiety, depression, PTSD, and schizophrenia **have been scientifically significant**. These results also demonstrate reduction of inflammation, which has beneficial implications for pain. Additionally, this can be used to decrease opioid addiction effects and schizophrenia-related symptoms. **Mentanine**[®] a scientifically developed and formulated medical product is tasteless and can be produced as a water-soluble liquid or powder, with substantially improved bioavailability.

Dr. Laviolette (of Western University) stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other approved CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising anti-epilepsy treatment, which I believe makes the formulation even more promising for these applications.”

Mentanine® Pre-clinical trials:

1. Indicated 10 times + the efficacy as compared to CBD molecules alone
2. Reduced Anxiety, Depression, PTSD and Addictive effects.
3. Showed significant reduction of inflammation, which can be beneficial for pain management.

This formulation can be administrated with a significantly faster rate of absorption and significantly smaller doses compared to other CBD medications, therefore, reducing or even eliminating the negative side effects of liver toxicity caused by high consumption of CBD oils available today.

Mentabinol® (THC + L-Theanine)

This medical cannabis formulation is a *safer alternative* to all other THC products, addressing anxiety, depression, and schizophrenia, while protecting all THC users from negative psychiatric side-effects. The Company has applied to Health Canada and is waiting for approval to produce, sell and export **Mentabinol®** under the Cannabis Act.

Mentabinol® Pre-clinical trials:

1. Reversal of depression-like and schizophrenia related symptoms
2. Complete blockage of memory impairment
3. Complete blockage of hyperactive activity
4. Complete blockage of gene vulnerability.

CanaQuest's wholly owned subsidiary, **ADC BioMedical Corp**, was awarded a cannabis and cannabinoid products, Sales/Purchase, Import/Export license from Health Canada for Medical purposes. CanaQuest is launching **Mentanine®**, scientifically developed, soon, which will be available to patients, physicians, clinics, and Health Canada licensed entities. The Company is also positioned to launch **Mentabinol®** upon regulatory approval. Licenced GMP Contract Manufacturers in Canada and USA, capable of formulating, processing, and packaging have been selected to start production. As well, the Company is in discussions with several parties regarding domestic and international distribution.

Management

Our team has more than 150 years of experience in management, design/process, commercialization, product development, accounting/CFO, government affairs (regulations) and pharmaceutical marketing/sales. A Scientific Advisory Board and Marketing/Sales Advisory Board are being formalized.

Supply, Processing and Bioavailability

CBD and THC suppliers/processors (partners) of our formulated products have the capability of producing tasteless medical grade CBD and THC water soluble liquids and powders, with improved bioavailability.

Products, Marketing and Sales

Our extremely experienced US Branding and Marketing team has been selected and our execution plan is in place to roll out our first CBD formulated product, Mentanine® in September/October 2020.

e-commerce – Medical Cannabis Sales

CanaQuest has developed a customized (fully Health Canada compliant) e-commerce website www.canaqueststore.com to sell directly to its patients as well as through its online distribution channel partners and globally where federally permitted.

The Company won the Go Global Awards, 2019, "Business of the Year – Category of Life Science", presented by the International Trade Council.

Paul Ramsay, President, CanaQuest Medical Corp. Tel.: 416-704-3040 paul@canaquest.com